{
    "status": "ok",
    "totalResults": 380,
    "articles": [
        {
            "source": {
                "id": null,
                "name": "ReadWrite"
            },
            "author": "Radek Zielinski",
            "title": "From free speech to paid speech the: implications of X\u2019s pay to reply",
            "description": "X, the platform formerly known as Twitter and now under the direction of billionaire Elon Musk, has unveiled its latest [\u2026]\nThe post From free speech to paid speech the: implications of X\u2019s pay to reply appeared first on ReadWrite.",
            "url": "https://readwrite.com/x-pay-to-reply-policy-limits-free-speech/",
            "urlToImage": "https://readwrite.com/wp-content/uploads/2023/10/free-speech-to-paid-speech.jpg",
            "publishedAt": "2023-10-10T21:09:20Z",
            "content": "X, the platform formerly known as Twitter and now under the direction of billionaire Elon Musk, has unveiled its latest controversial feature: allowing users to restrict replies to their posts only f\u2026 [+3510 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Ana Faguy, Forbes Staff, \n Ana Faguy, Forbes Staff\n https://www.forbes.com/sites/anafaguy/",
            "title": "Eli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion\u2014A Nearly 90% Premium",
            "description": "American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manu...",
            "url": "https://www.forbes.com/sites/anafaguy/2023/10/03/eli-lilly-acquiring-cancer-therapy-developer-for-14-billion-a-nearly-90-premium/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/651c162ee4aeaafb7749b1d3/0x0.jpg?format=jpg&crop=2707,1521,x0,y85,safe&width=1200",
            "publishedAt": "2023-10-03T14:21:34Z",
            "content": "American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manufacturers struggle to keep up wi\u2026 [+2192 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "benzinga.com",
            "title": "Why Eli Lilly Stock's Dream Run May Not Be Over Yet",
            "description": "Eli Lilly & Co. LLY has been a high-flier among the mega-cap pharma stocks this year, as the company leverages the obesity drug craze. Prominent Tesla investor and Future Fund Manager Gary Black weighed in on the stock\u2019s run-up and its future trajectory. What\u2026",
            "url": "https://biztoc.com/x/8f045ae845afbe01",
            "urlToImage": "https://c.biztoc.com/p/8f045ae845afbe01/s.webp",
            "publishedAt": "2023-10-12T10:06:12Z",
            "content": "Eli Lilly &amp; Co. LLY has been a high-flier among the mega-cap pharma stocks this year, as the company leverages the obesity drug craze. Prominent Tesla investor and Future Fund Manager Gary Black \u2026 [+280 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "barrons.com",
            "title": "HP Inc., Oddity, WK Kellogg, Point Biopharma, Airbnb, and More Stock Market Movers",
            "description": "HP Inc. shares are double upgraded to Buy at BofA, Oddity Tech stock soars after the beauty-products company issues third-quarter guidance higher than initial forecasts, and Eli Lilly is buying Point Biopharma for $1.4 billion.#hpinc #odditytech #elililly #po\u2026",
            "url": "https://biztoc.com/x/c0398c70a7401c43",
            "urlToImage": "https://c.biztoc.com/p/c0398c70a7401c43/og.webp",
            "publishedAt": "2023-10-03T12:24:27Z",
            "content": "HP Inc. shares are double upgraded to Buy at BofA, Oddity Tech stock soars after the beauty-products company issues third-quarter guidance higher than initial forecasts, and Eli Lilly is buying Point\u2026 [+109 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "UNICEF USA Contributor, UNICEF USA, \n UNICEF USA Contributor, UNICEF USA\n https://www.forbes.com/sites/unicefusa/people/unicefusacontributor/",
            "title": "A Life Transformed By Noncommunicable Disease Screening",
            "description": "UNICEF works with governments, partners and donors to strengthen primary health systems and improve the screening and treatment of childhood NCDs.",
            "url": "https://www.forbes.com/sites/unicefusa/2023/09/19/a-life-transformed-by-noncommunicable-disease-screening/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/6509a096c3091f86e401661d/0x0.jpg?format=jpg&width=1200",
            "publishedAt": "2023-09-19T13:34:15Z",
            "content": "UNICEF works with governments, partners and donors to strengthen primary health systems and improve the screening and treatment of childhood NCDs.\r\nChifundo, 10, visits Neno District Hospital in Mala\u2026 [+5089 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "GuruFocus Research",
            "title": "Lilly Endowment Inc. Reduces Stake in Eli Lilly and Co.",
            "description": "On October 11, 2023, Lilly Endowment Inc., a private philanthropic foundation, executed a significant transaction in the stock market.  The firm reduced its ...",
            "url": "https://finance.yahoo.com/news/lilly-endowment-inc-reduces-stake-090159668.html",
            "urlToImage": "https://s.yimg.com/ny/api/res/1.2/ufYc7Uo0epEtGSSlyd.cqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NzE-/https://media.zenfs.com/en/us.finance.gurufocus/8958539c0b447519931d2029d544354e",
            "publishedAt": "2023-10-13T09:01:59Z",
            "content": "On October 11, 2023, Lilly Endowment Inc., a private philanthropic foundation, executed a significant transaction in the stock market. The firm reduced its holdings in Eli Lilly and Co., a leading ph\u2026 [+3834 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Thedailyupside.com"
            },
            "author": "newsfeedback@fool.com (Griffin Kelly from The Daily Upside)",
            "title": "The Anti-obesity Drug Market Is About to Get More Crowded",
            "description": "Obesity is an epidemic that affects more than 40% of all American adults, and it's creating a feeding frenzy for investors. With the rise of...",
            "url": "https://www.thedailyupside.com/industries/the-anti-obesity-drug-market-is-about-to-get-more-crowded/",
            "urlToImage": "https://www.thedailyupside.com/wp-content/uploads/2023/09/september-28-2023-1.jpeg",
            "publishedAt": "2023-09-28T15:00:15Z",
            "content": "Obesity is an epidemic that affects more than 40% of all American adults, and its creating a feeding frenzy for investors.\r\nWith the rise of obesity-fighting medications from pharmaceutical companies\u2026 [+2444 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Leefang.com"
            },
            "author": "Lee Fang",
            "title": "Behind OZEMPIC Media Buzz, Undisclosed Drugmaker Money...",
            "description": "Physicians, activists, and celebrities are quoted by newspapers and media outlets touting Ozempic without disclosing financial ties to the drugmaker.",
            "url": "https://www.leefang.com/p/behind-ozempic-media-buzz-undisclosed",
            "urlToImage": "https://substackcdn.com/image/fetch/w_1200,h_600,c_fill,f_jpg,q_auto:good,fl_progressive:steep,g_auto/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c5df4c7-61ac-4de1-964e-89218509483a_1024x684.jpeg",
            "publishedAt": "2023-09-27T00:16:37Z",
            "content": "Celebrities, physicians, patient advocacy groups, public health experts, academics, and a variety of community leaders have appeared in dozens of media outlets to tout the wonders of a new class of w\u2026 [+6688 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "GuruFocus Research",
            "title": "Unveiling Eli Lilly and Co (LLY)'s Value: Is It Really Priced Right? A Comprehensive Guide",
            "description": "Exploring the intrinsic value of Eli Lilly and Co (LLY) using GuruFocus's proprietary GF Value",
            "url": "https://finance.yahoo.com/news/unveiling-eli-lilly-co-lly-163311185.html",
            "urlToImage": "https://media.zenfs.com/en/us.finance.gurufocus/f31e7209fd63068cab623510a7b93e03",
            "publishedAt": "2023-09-21T16:33:11Z",
            "content": "The stock of Eli Lilly and Co (NYSE:LLY) has been a topic of interest for many investors, given its recent performance. The stock has seen a daily loss of -3.78%, but a 3-month gain of 22.79%. Couple\u2026 [+4310 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "UPI.com"
            },
            "author": "Cara Murez, HealthDay News",
            "title": "Eli Lilly sues wellness centers, compounding pharmacies over Mounjaro",
            "description": "Another diabetes drug maker is taking legal action against businesses in several states, alleging that they're \"fraudulently claiming\" that their compounded ...",
            "url": "https://www.upi.com/Health_News/2023/09/20/diabetes-drug-maker-Mounjaro/1281695215938/",
            "urlToImage": "https://media.zenfs.com/en/united_press_international_articles_356/08f388f15d6ed66c6e46749fd11d5b08",
            "publishedAt": "2023-09-20T14:04:33Z",
            "content": "Another diabetes drug maker is taking legal action against businesses in several states, alleging that they're \"fraudulently claiming\" that their compounded products are the same as its medication.\r\n\u2026 [+2381 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Quartz India"
            },
            "author": "Scott Nover",
            "title": "The US government has mounting evidence that Elon Musk violated Twitter\u2019s data privacy agreement",
            "description": "When Elon Musk bought Twitter for $44 billion last year, he became the steward of a company enmeshed in longstanding data-privacy problems with the US government.Read more...",
            "url": "https://qz.com/the-us-government-has-mounting-evidence-that-elon-musk-1850838006",
            "urlToImage": "https://i.kinja-img.com/gawker-media/image/upload/c_fill,f_auto,fl_progressive,g_center,h_675,pg_1,q_80,w_1200/2d8d70234e5a93c7770c562e33815381.jpg",
            "publishedAt": "2023-09-14T16:09:00Z",
            "content": "When Elon Musk bought Twitter for $44 billion last year, he became the steward of a company enmeshed in longstanding data-privacy problems with the US government.\r\nTwitter had been operating under a \u2026 [+5086 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "GuruFocus Research",
            "title": "EVP, ERM & CECO Alonzo Weems Sells 1,148 Shares of Eli Lilly and Co",
            "description": "On September 12, 2023, Alonzo Weems, the Executive Vice President, Ethics and Compliance Officer of Eli Lilly and Co (NYSE:LLY), sold 1,148 shares of the...",
            "url": "https://finance.yahoo.com/news/evp-erm-ceco-alonzo-weems-050227463.html",
            "urlToImage": "https://media.zenfs.com/en/us.finance.gurufocus/f31e7209fd63068cab623510a7b93e03",
            "publishedAt": "2023-09-14T05:02:27Z",
            "content": "On September 12, 2023, Alonzo Weems, the Executive Vice President, Ethics and Compliance Officer of Eli Lilly and Co (NYSE:LLY), sold 1,148 shares of the company. This move is part of a series of tra\u2026 [+2111 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Science Daily"
            },
            "author": null,
            "title": "Adaptive, efficient multi-arm phase 2 clinical trial for glioblastoma",
            "description": "An innovative phase 2 clinical trial designed to find new potential treatments for glioblastoma has reported initial results. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of \u2026",
            "url": "https://www.sciencedaily.com/releases/2023/09/230918161559.htm",
            "urlToImage": "https://www.sciencedaily.com/images/scidaily-icon.png",
            "publishedAt": "2023-09-18T20:15:59Z",
            "content": "An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for gliobl\u2026 [+5197 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Brian Bushard, Forbes Staff, \n Brian Bushard, Forbes Staff\n https://www.forbes.com/sites/brianbushard/",
            "title": "Shortage Of Weight-Loss Drugs Like Wegovy And Ozempic Persist\u2014And Could For \u2018Some Years\u2019",
            "description": "Diabetes drugs Wegovy and Ozempic, which have gained popularity as weight-loss drugs, face major supply issues, drugmaker Novo Nordisk admitted, as the company struggles with surging demand.",
            "url": "https://www.forbes.com/sites/brianbushard/2023/09/16/shortage-of-weight-loss-drugs-like-wegovy-and-ozempic-persist-and-could-for-some-years/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/6505c91cb7a38a290928ff0b/0x0.jpg?format=jpg&crop=3326,1869,x0,y169,safe&width=1200",
            "publishedAt": "2023-09-16T15:27:50Z",
            "content": "Surging demand for drugmaker Novo Nordisks highly popular diabetes treatments Ozempic and Wegovy, which have become household names in the U.S. as weight-loss medications, has created a major supply \u2026 [+3547 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Patrick  Wingrove",
            "title": "Eli Lilly sues over US sales of bogus Mounjaro for weight loss",
            "description": "Eli Lilly on Tuesday said it was suing 10 U.S. medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide...",
            "url": "https://finance.yahoo.com/news/eli-lilly-sues-over-us-190641447.html",
            "urlToImage": "https://media.zenfs.com/en/reuters-finance.com/817d97fc82b31ed17ff6ad256814b828",
            "publishedAt": "2023-09-19T19:06:41Z",
            "content": "By Patrick Wingrove\r\n(Reuters) - Eli Lilly on Tuesday said it was suing 10 U.S. medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, the act\u2026 [+2694 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Patrick  Wingrove",
            "title": "Eli Lilly sues over US sales of bogus Mounjaro for weight loss",
            "description": "Eli Lilly on Tuesday said it was suing 10 U.S. medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide...",
            "url": "https://ca.finance.yahoo.com/news/eli-lilly-sues-over-us-190641574.html",
            "urlToImage": "https://media.zenfs.com/en/reuters.com/817d97fc82b31ed17ff6ad256814b828",
            "publishedAt": "2023-09-19T19:06:41Z",
            "content": "By Patrick Wingrove\r\n(Reuters) - Eli Lilly on Tuesday said it was suing 10 U.S. medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, the act\u2026 [+2694 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Quartz India"
            },
            "author": "Ananya Bhattacharya",
            "title": "If Ozempic is already hurting junk food sales, what other sectors should be on alert?",
            "description": "The rising popularity of weight-management drugs like Ozempic and WeGovy is not only killing appetites, but also growth forecasts for the packaged-food industry.Read more...",
            "url": "https://qz.com/if-ozempic-is-already-hurting-junk-food-sales-what-oth-1850905909",
            "urlToImage": "https://i.kinja-img.com/image/upload/c_fill,f_auto,fl_progressive,g_center,h_675,pg_1,q_80,w_1200/e6d1037b2fa550005daad77331c7b942.jpg",
            "publishedAt": "2023-10-06T14:17:17Z",
            "content": "The rising popularity of weight-management drugs like Ozempic and WeGovy is not only killing appetites, but also growth forecasts for the packaged-food industry.\r\nThe GLP-1 drugs, which mimic a hormo\u2026 [+5012 chars]"
        },
        {
            "source": {
                "id": "al-jazeera-english",
                "name": "Al Jazeera English"
            },
            "author": "Al Jazeera",
            "title": "How global firms are reacting to the Israel-Hamas conflict",
            "description": "Companies ranging from airlines to banks have shut operations in Israel, asking their employees to work from home.",
            "url": "https://www.aljazeera.com/economy/2023/10/10/how-global-firms-are-reacting-to-the-israel-hamas-conflict",
            "urlToImage": "https://www.aljazeera.com/wp-content/uploads/2023/10/2023-06-05T000000Z_2003550247_RC27D1A33Y3M_RTRMADP_3_ISRAEL-TEL-AVIV-CITYSCAPE-1696935829.jpg?resize=1920%2C1440",
            "publishedAt": "2023-10-10T12:05:29Z",
            "content": "Global companies with a presence in Israel have suspended operations or asked employees to work from home as the country wages war on Hamas in the Gaza Strip.\r\nBelow are some of the steps being taken\u2026 [+2739 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Insurance Journal"
            },
            "author": "Admin",
            "title": "Eli Lilly Sues Businesses Selling Knockoff Versions of Mounjaro",
            "description": "Eli Lilly & Co. is suing medical spas, wellness centers and compounding pharmacies in various US states that sell unapproved versions of its blockbuster diabetes drug Mounjaro, which is frequently used off-label for weight loss. In lawsuits Lilly said it \u2026",
            "url": "https://www.insurancejournal.com/news/national/2023/09/20/741067.htm",
            "urlToImage": "https://www.insurancejournal.com/app/uploads/2023/09/diabetes-drug-mounjaroeli-getty-scaled.jpg",
            "publishedAt": "2023-09-20T06:24:17Z",
            "content": "Eli Lilly &amp; Co. is suing medical spas, wellness centers and compounding pharmacies in various US states that sell unapproved versions of its blockbuster diabetes drug Mounjaro, which is frequentl\u2026 [+2732 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Georgina McKay",
            "title": "Obesity-Drug Mania Propels Top Stock Fund to Beat 94% of Peers",
            "description": "(Bloomberg) -- A top-performing equity fund with years-long investments in the insulin makers behind the recent weight-loss stock frenzy is betting the rally...",
            "url": "https://finance.yahoo.com/news/obesity-drug-mania-propels-top-060000337.html",
            "urlToImage": "https://media.zenfs.com/en/bloomberg_markets_842/eb0ca6e2a47e562d2c98296cef2cf04e",
            "publishedAt": "2023-09-20T06:00:00Z",
            "content": "(Bloomberg) -- A top-performing equity fund with years-long investments in the insulin makers behind the recent weight-loss stock frenzy is betting the rally has further to run.\r\nMost Read from Bloom\u2026 [+2586 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Arianna Johnson, Forbes Staff, \n Arianna Johnson, Forbes Staff\n https://www.forbes.com/sites/ariannajohnson/",
            "title": "Weight Loss Drugs Like Ozempic Boost Risk Of Serious Stomach Issues\u2014But It\u2019s Still Rare",
            "description": "Drugs like Ozempic can boost the risk of some gastrointestinal problems in weight loss patients, compared to other weight loss drugs, a study has revealed for the first time\u2014but the risk remains low.",
            "url": "https://www.forbes.com/sites/ariannajohnson/2023/10/05/weight-loss-drugs-like-ozempic-boost-risk-of-serious-stomach-issues-but-its-still-rare/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/651ed91ed2c18bf2db401804/0x0.jpg?format=jpg&width=1200",
            "publishedAt": "2023-10-05T15:42:38Z",
            "content": "Popular weight loss drugs like Ozempic, Wegovy, Saxenda and Rybelsus can lead to an increased risk of serious stomach problems like gastroparesis and bowel obstruction compared to other weight loss d\u2026 [+6101 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Blake Brittain",
            "title": "US judge overturns Eli Lilly's $176.5 million loss in Teva patent case",
            "description": "Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found...",
            "url": "https://finance.yahoo.com/news/us-judge-overturns-eli-lillys-203352787.html",
            "urlToImage": "https://media.zenfs.com/en/reuters-finance.com/0534d7644063ff8bffc0b7c67c4a186e",
            "publishedAt": "2023-09-26T20:33:52Z",
            "content": "By Blake Brittain\r\n(Reuters) - Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine \u2026 [+1186 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Insurance Journal"
            },
            "author": "Admin",
            "title": "Eli Lilly Settles New Jersey Whistleblower Allegations Over Manufacturing Practices",
            "description": "Eli Lilly and Co. and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs, according to court \u2026",
            "url": "https://www.insurancejournal.com/news/east/2023/10/03/742591.htm",
            "urlToImage": null,
            "publishedAt": "2023-10-03T05:00:06Z",
            "content": "Eli Lilly and Co. and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one \u2026 [+1939 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Lisa Pham, Madison Muller and Naomi Kresge",
            "title": "A Stock Investor\u2019s Guide to Navigating Weight Loss Opportunities",
            "description": "(Bloomberg) -- For investors, there's a whole lot more to the boom in demand for weight-loss drugs than the rising stock prices of Novo Nordisk A/S and Eli...",
            "url": "https://finance.yahoo.com/news/stock-investor-guide-navigating-weight-073036817.html",
            "urlToImage": "https://s.yimg.com/ny/api/res/1.2/bwN9qaDCFkel3eaixhPjwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03MDA-/https://media.zenfs.com/en/bloomberg_markets_842/011ae6f758593eb42e58e9323488fdaf",
            "publishedAt": "2023-09-16T07:30:36Z",
            "content": "(Bloomberg) -- For investors, there's a whole lot more to the boom in demand for weight-loss drugs than the rising stock prices of Novo Nordisk A/S and Eli Lilly &amp; Co.\r\nMost Read from Bloomberg\r\n\u2026 [+9151 chars]"
        },
        {
            "source": {
                "id": "rt",
                "name": "RT"
            },
            "author": "RT",
            "title": "Prozac shortage reported in Russia",
            "description": "Russia has reportedly faced an acute Prozac shortage in recent months after its US-based manufacturer decided to withdraw from the market Read Full Article at RT.com",
            "url": "https://www.rt.com/russia/583074-prozac-shortage-reported-russia/",
            "urlToImage": "https://mf.b37mrtl.ru/files/2023.09/article/6505f67b2030275f981e7cbf.jpg",
            "publishedAt": "2023-09-16T18:42:05Z",
            "content": "Russia is experiencing a severe shortage of the popular antidepressant drug, Prozac, RBK news outlet reported on Saturday. It comes six months after the US manufacturer of the pill, Eli Lilly and Com\u2026 [+2298 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Radaronline.com"
            },
            "author": "Connor Surmonte",
            "title": "Russia Suffers Mental Health Crisis as Citizens Grow Depressed Over Putin's War in Ukraine: Report",
            "description": "The use of the depression medication Prozac reportedly rose by 63% shortly after Vladimir Putin first invaded Ukraine in February 2022.",
            "url": "https://radaronline.com/p/russia-mental-health-crisis-citizens-depressed-putin-war-ukraine/",
            "urlToImage": "https://media.radaronline.com/brand-img/heHEhHgwB/1200x628/russia-mental-health-crisis-citizens-depressed-putin-war-ukrainejpg-1695140449407.jpg",
            "publishedAt": "2023-09-19T17:30:00Z",
            "content": "The country has been increasingly affected by a shortage of top Western goods due to sanctions and self-imposed curbs on sales. \r\nThe United States company Eli Lilly, which produces Prozac, announced\u2026 [+252 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Vandana Singh",
            "title": "Elon Musk-Backed Neuralink Starts Participant Enrollment For Paralysis, Eli Lilly Cracks Down on Counterfeit Weight Loss Drugs, Meta Looks to Capitalize on India's In-App Payment Surge: Today's Top Stories",
            "description": "Benzinga Elon Musk-Backed Brain Implant Firm Neuralink Starts Participant Enrollment In Brain Implant Human Trial For Paralysis Elon Musk's brain-computer...",
            "url": "https://finance.yahoo.com/news/elon-musk-backed-neuralink-starts-155614017.html",
            "urlToImage": "https://media.zenfs.com/en/Benzinga/cc49d7f784e8029a1fe1447a7ed9def5",
            "publishedAt": "2023-09-20T15:56:14Z",
            "content": "Benzinga\r\nElon Musk-Backed Brain Implant Firm Neuralink Starts Participant Enrollment In Brain Implant Human Trial For Paralysis\r\n<ul><li>Elon Musk's\u00a0brain-computer interface company,\u00a0Neuralink, has \u2026 [+9165 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Trefis Team, Contributor, \n Trefis Team, Contributor\n https://www.forbes.com/sites/greatspeculations/people/trefis/",
            "title": "Will DexCom Stock Recover To Its Pre-Inflation Shock Highs Of $160?",
            "description": "The notable increase in DexCom\u2019s revenues over recent quarters has also contributed to the stock recovery.",
            "url": "https://www.forbes.com/sites/greatspeculations/2023/09/18/will-dexcom-stock-recover-to-its-pre-inflation-shock-highs-of-160/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/6507c744660465a285935f6b/0x0.jpg?format=jpg&width=1200",
            "publishedAt": "2023-09-18T13:00:00Z",
            "content": "Ed Gamble and Roxy Horner, who live with Type 1 diabetes, at the Dexcom's \"No Pricks Parlour\" ... [+] vintage ice cream truck, handing out free ice cream on London's South Bank to celebrate Diabetes \u2026 [+5706 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "GuruFocus Research",
            "title": "JW Asset Management, LLC Increases Stake in TerrAscend Corp",
            "description": "This article provides an in-depth analysis of the transaction, the profiles of the guru and the traded company, and the potential implications for value...",
            "url": "https://finance.yahoo.com/news/jw-asset-management-llc-increases-190805667.html",
            "urlToImage": "https://s.yimg.com/ny/api/res/1.2/cVg327j5aQvsIFiBo1u6Hw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NzE-/https://media.zenfs.com/en/us.finance.gurufocus/4abf75d66b008a2c02e7a66a8f0425e2",
            "publishedAt": "2023-09-19T19:08:05Z",
            "content": "On September 15, 2023, JW Asset Management, LLC (Trades, Portfolio), a prominent investment firm, added to its holdings in TerrAscend Corp (TSNDF), a leading cannabis company based in Canada. This ar\u2026 [+3571 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Vandana Singh",
            "title": "Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories",
            "description": "Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO Alibaba Group Holding Limited (NYSE: BABA) stock is trading higher Wednesday as the...",
            "url": "https://finance.yahoo.com/news/apple-defends-19b-google-search-154747761.html",
            "urlToImage": "https://media.zenfs.com/en/Benzinga/7410c3c9c74deea38aac84a896d67852",
            "publishedAt": "2023-09-27T15:47:47Z",
            "content": "Benzinga\r\nAlibaba's Logistics Arm Cainiao Files For Hong Kong IPO\r\n<ul><li>Alibaba Group Holding Limited\u00a0(NYSE: BABA) stock is trading higher Wednesday as the company's logistics arm\u00a0Cainiao Smart Lo\u2026 [+8451 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Rob Toews, Contributor, \n Rob Toews, Contributor\n https://www.forbes.com/sites/robtoews/",
            "title": "10 Hypothetical Blockbuster AI M&A Deals",
            "description": "A wave of AI-related acquisitions is coming.",
            "url": "https://www.forbes.com/sites/robtoews/2023/10/02/10-hypothetical-blockbuster-ai-ma-deals/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/65185bfe96699717e8614931/0x0.jpg?format=jpg&crop=1743,980,x1,y33,safe&width=1200",
            "publishedAt": "2023-10-02T19:40:20Z",
            "content": "Meta CEO Mark Zuckerberg, Nvidia CEO Jensen Huang and Microsoft CEO Satya Nadella are among the ... [+] executives who may pursue splashy AI-related acquisitions in the months ahead.\r\nGetty Images\r\nA\u2026 [+13737 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Rob Toews, Contributor, \n Rob Toews, Contributor\n https://www.forbes.com/sites/robtoews/",
            "title": "10 Blockbuster AI M&A Deals On The Horizon",
            "description": "A wave of big AI-related acquisitions is coming.",
            "url": "https://www.forbes.com/sites/robtoews/2023/10/01/10-blockbuster-ai-ma-deals-on-the-horizon/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/65185bfe96699717e8614931/0x0.jpg?format=jpg&crop=1744,981,x0,y49,safe&width=1200",
            "publishedAt": "2023-10-01T23:23:45Z",
            "content": "Meta CEO Mark Zuckerberg, Nvidia CEO Jensen Huang and Microsoft CEO Satya Nadella are among the ... [+] executives who may pursue splashy AI-related acquisitions in the months ahead.\r\nGetty Images\r\nA\u2026 [+13557 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "MedCity News"
            },
            "author": "FRANK VINLUAN - MEDCITY NEWS",
            "title": "Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy Manufacturing",
            "description": "Syntax Bio\u2019s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that\u2019s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potentia\u2026",
            "url": "https://medcitynews.com/2023/09/startup-syntax-bio-leverages-crispr-to-transform-cell-therapy-manufacturing/",
            "urlToImage": "https://medcitynews.com/uploads/2023/09/islet-cells-pancreas.jpg",
            "publishedAt": "2023-09-25T14:03:35Z",
            "content": "Cell therapies are already here, with treatments now available for some cancers and rare diseases. But bringing such living medicines to more patients presents both scientific and financial challenge\u2026 [+6617 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Raw Story"
            },
            "author": "Matthew Chapman",
            "title": "Hitler-quoting former school board member arrested for brandishing gun at her tenant",
            "description": "A former school board member in Colorado Springs has been arrested following an altercation with a tenant involving a handgun, reported Law & Crime.According to the tenant, identified in records as \"Andrew,\" he had been renting a room from 66-year-old Ivy Liu\u2026",
            "url": "https://www.rawstory.com/hitler-quoting-gun-incident/",
            "urlToImage": "https://www.rawstory.com/media-library/gun-with-bullets.jpg?id=33731223&width=1200&height=600&coordinates=0%2C25%2C0%2C25",
            "publishedAt": "2023-10-05T22:29:40Z",
            "content": "But that's just a fraction of Christie's reported earnings. He earned more then $1.6 million from his consulting firm, Christie 55 Solutions, nearly $700,000 from his law firm via salary and his part\u2026 [+1670 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Raw Story"
            },
            "author": "David Edwards",
            "title": "'We've lost everything, every dime': Mike Lindell explains why he can't pay his legal bills",
            "description": "MyPillow CEO Mike Lindell revealed on Thursday that he had \"lost everything\" after several of his lawyers quit over legal debts.In a court filing Thursday, law firm Parker Daniels Kibort said Lindell owed millions of dollars. The firm represented him in three\u2026",
            "url": "https://www.rawstory.com/mike-lindell-lawyers/",
            "urlToImage": "https://www.rawstory.com/media-library/mypillow-ceo-mike-lindell-speaking-with-attendees-at-the-2020-student-action-summit.jpg?id=29771051&width=1200&height=600&coordinates=0%2C25%2C0%2C25",
            "publishedAt": "2023-10-05T21:08:45Z",
            "content": "But that's just a fraction of Christie's reported earnings. He earned more then $1.6 million from his consulting firm, Christie 55 Solutions, nearly $700,000 from his law firm via salary and his part\u2026 [+1670 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Raw Story"
            },
            "author": "Matthew Chapman",
            "title": "Battleground state Republicans are refusing campaign donations from Marjorie Taylor Greene: report",
            "description": "Rep. Marjorie Taylor Greene (R-GA) is contributing money to fellow House Republicans \u2014 but some of those facing tougher elections don't want to be backed by her, reported Business Insider on Thursday.According to the report, Greene, a far-right lawmaker infam\u2026",
            "url": "https://www.rawstory.com/marjorie-taylor-greene-2665810267/",
            "urlToImage": "https://www.rawstory.com/media-library/rep-marjorie-taylor-greene-has-lost-big-money-investing-in-trumps-truth-social-venture.jpg?id=33351411&width=1200&height=600&coordinates=0%2C217%2C0%2C217",
            "publishedAt": "2023-10-05T21:02:15Z",
            "content": "But that's just a fraction of Christie's reported earnings. He earned more then $1.6 million from his consulting firm, Christie 55 Solutions, nearly $700,000 from his law firm via salary and his part\u2026 [+1670 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Raw Story"
            },
            "author": "David McAfee",
            "title": "'Tip of the iceberg': Experts pounce on Trump nuclear secrets bombshell",
            "description": "ABC News reported on Thursday that ex-president Donald Trump had shared nuclear secrets with a billionaire at his golf club, and experts were quick to react to how the report could affect Trump's current criminal case on classified document handling.Trump, wh\u2026",
            "url": "https://www.rawstory.com/trump-nuclear-reactions/",
            "urlToImage": "https://www.rawstory.com/media-library/image.jpg?id=27419245&width=1200&height=600&coordinates=0%2C25%2C0%2C25",
            "publishedAt": "2023-10-05T22:09:23Z",
            "content": "But that's just a fraction of Christie's reported earnings. He earned more then $1.6 million from his consulting firm, Christie 55 Solutions, nearly $700,000 from his law firm via salary and his part\u2026 [+1670 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Raw Story"
            },
            "author": "Matthew Chapman",
            "title": "'Sick to my stomach': Ex-Pence aide aghast Trump shared nuclear info with foreign national",
            "description": "A bombshell report on Thursday revealed that shortly after leaving office, former President Donald Trump discussed U.S. nuclear submarine secrets with an Australian billionaire who happened to be a member of Trump's Mar-a-Lago country club.Former Mike Pence n\u2026",
            "url": "https://www.rawstory.com/trump-2665810962/",
            "urlToImage": "https://www.rawstory.com/media-library/image.png?id=24816888&width=1200&height=600&coordinates=0%2C15%2C0%2C15",
            "publishedAt": "2023-10-05T22:57:13Z",
            "content": "But that's just a fraction of Christie's reported earnings. He earned more then $1.6 million from his consulting firm, Christie 55 Solutions, nearly $700,000 from his law firm via salary and his part\u2026 [+1670 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Dow Jones",
            "title": "Point Biopharma Shares Surge Premarket on Takeover by Eli Lilly",
            "description": "(marketscreener.com) \n By Colin Kellaher \n\n\n Shares of Point Biopharma Global took flight in premarket trading Tuesday after the radiopharmaceutical company agreed to be acquired by drugmaker Eli Lilly at a rich premium. \n\n Eli Lilly said it will pay $1.4 bil\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Point-Biopharma-Shares-Surge-Premarket-on-Takeover-by-Eli-Lilly-44972087/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-03T11:44:02Z",
            "content": "By Colin Kellaher \r\nShares of Point Biopharma Global took flight in premarket trading Tuesday after the radiopharmaceutical company agreed to be acquired by drugmaker Eli Lilly at a rich premium. \r\nE\u2026 [+950 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "The Boston Globe"
            },
            "author": "Jonathan Saltzman",
            "title": "Karuna plans to more than double its workforce if schizophrenia drug is approved",
            "description": "Karuna, which began clinical trials of a first-of-its-kind schizophrenia drug called KarXT in 2016, has grown rapidly from about 20 employees in 2020 to more than 300 today.",
            "url": "https://www.bostonglobe.com/2023/10/12/business/karuna-schizophrenia-drug-workforce/",
            "urlToImage": "https://bostonglobe-prod.cdn.arcpublishing.com/resizer/o0euC8jxS_6XPTwxHFShqh_bfZM=/506x0/cloudfront-us-east-1.images.arcpublishing.com/bostonglobe/XL5IVLQJLVBW3PJAYT4GGGVYQY.JPEG",
            "publishedAt": "2023-10-12T12:30:36Z",
            "content": "I dont want to make it sound like were overconfident, he said. But I think were confident in the development plan weve executed and were preparing for the launch of KarXT in the second half of next y\u2026 [+3290 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "GuruFocus Research",
            "title": "JW Asset Management, LLC Increases Stake in TerrAscend Corp",
            "description": "On September 12, 2023, JW Asset Management, LLC added 15,000 shares of TerrAscend Corp (TSNDF) to its portfolio.  The shares were acquired at a price of...",
            "url": "https://finance.yahoo.com/news/jw-asset-management-llc-increases-150334008.html",
            "urlToImage": "https://s.yimg.com/ny/api/res/1.2/rlxddrGXyDtCe8xGyGsthg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NzE-/https://media.zenfs.com/en/us.finance.gurufocus/c9d2b559d6adc01b6c08acaa132e2f27",
            "publishedAt": "2023-09-14T15:03:34Z",
            "content": "On September 12, 2023, JW Asset Management, LLC added 15,000 shares of TerrAscend Corp (TSNDF) to its portfolio. The shares were acquired at a price of $2.11 each, bringing the firm's total holdings \u2026 [+3783 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investor's Business Daily"
            },
            "author": "Investor's Business Daily",
            "title": "9 'Unstoppable' Stocks Deliver Big Gains And No Pain To Investors",
            "description": "Risk and reward are supposed to be attached at the hip for S&P 500 stocks.",
            "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-unstoppable-stocks-deliver-big-gains-and-no-pain-to-investors/",
            "urlToImage": "https://www.investors.com/wp-content/uploads/2021/04/Stock-moneypile-03-adobe.jpg",
            "publishedAt": "2023-10-11T12:00:18Z",
            "content": "Risk and reward are supposed to be attached at the hip for S&amp;P 500 stocks. But a small group of stocks are delivering all gain and no pain.\r\nXNine stocks in the S&amp;P 500, including Meta Platfo\u2026 [+3874 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Raw Story"
            },
            "author": "Alexandria Jacobson, Investigative Reporter",
            "title": "Chris Christie earned more from ABC News than he would as president: new documents",
            "description": "Former New Jersey Gov. Chris Christie's gig with ABC News paid him more than what he'd earn as president of the United States, according to a new federal financial filing.Christie \u2014 now running as a long-shot Republican presidential candidate \u2014 reported earni\u2026",
            "url": "https://www.rawstory.com/raw-investigates/chris-christie-abc-news-salary/",
            "urlToImage": "https://www.rawstory.com/media-library/image.jpg?id=33793544&width=1200&height=600&coordinates=0%2C717%2C0%2C718",
            "publishedAt": "2023-10-05T21:55:59Z",
            "content": "Former New Jersey Gov. Chris Christie's gig with ABC News paid him more than what he'd earn as president of the United States, according to a new federal financial filing.\r\nChristie now running as a \u2026 [+2123 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "CNBC"
            },
            "author": "Samantha Subin",
            "title": "Stocks making the biggest moves premarket: Warby Parker, HP, Point Biopharma and more",
            "description": "These are the stocks posting the largest moves in premarket trading.",
            "url": "https://www.cnbc.com/2023/10/03/stocks-making-the-biggest-moves-premarket-wrby-hpq-pnt.html",
            "urlToImage": "https://image.cnbcfm.com/api/v1/image/106949563-1632932549507WRBY-OB-Photo-210929-PRESS-19.jpg?v=1696334271&w=1920&h=1080",
            "publishedAt": "2023-10-03T11:57:00Z",
            "content": "Check out the companies making headlines before the bell.\r\nWarby Parker Warby Parker jumped about 4% after Evercore ISI upgraded the eyeglass retailer to an outperform rating, saying that shares coul\u2026 [+1696 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "PRNewswire",
            "title": "Lilly Announces Leadership Transitions",
            "description": "(marketscreener.com) \n\nINDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company today announced changes to its executive leadership team.\nMike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the e\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Lilly-Announces-Leadership-Transitions-44980896/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-04T10:46:04Z",
            "content": "INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team.\r\nMike Mason, executive vice president and president of Lilly Dia\u2026 [+9458 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "prnewswire.com",
            "title": "Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies",
            "description": "PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire... #elilillyandcompany #lly #pnt #lilly",
            "url": "https://biztoc.com/x/7f4d01d7d5d2541b",
            "urlToImage": "https://c.biztoc.com/253/og.png",
            "publishedAt": "2023-10-03T12:42:16Z",
            "content": "PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire...\r\n#elilillyandcompany#lly#pnt#lilly\r\nThis\u2026 [+45 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "MarketWatch"
            },
            "author": "Steve Gelsi",
            "title": ": Point Biopharma Global\u2019s stock jumps more than 80% after Lilly merger deal",
            "description": "Point Biopharma Global, Inc.\u2019s PNT stock was up 83.4% in premarket trading on Tuesday after Eli Lilly & Co. LLY said it will pay $12.50 a share to acquire the Indianapolis-based cancer treatment company for about $1.4 billion. The purchase price amounts to an\u2026",
            "url": "https://www.marketwatch.com/story/point-biopharma-globals-stock-jumps-more-than-80-after-lilly-merger-deal-f8cff6a2",
            "urlToImage": "https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg",
            "publishedAt": "2023-10-03T10:56:00Z",
            "content": "Point Biopharma Global, Inc.s \r\n PNT,\r\n +0.22%\r\nstock was up 83.4% in premarket trading on Tuesday after Eli Lilly &amp; Co. \r\n LLY,\r\n +0.22%\r\nsaid it will pay $12.50 a share to acquire the Indianapo\u2026 [+502 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Zacks.com"
            },
            "author": "247patrick",
            "title": "3 Stocks to Focus on as Demand for Obesity Drugs Booms",
            "description": "The market for obesity and weight management drugs is attracting a lot of interest lately in the United States.",
            "url": "https://www.zacks.com/stock/news/2157743/3-stocks-to-focus-on-as-demand-for-obesity-drugs-booms?cid=",
            "urlToImage": "https://247wallst.com/wp-content/uploads/2021/07/imageForEntry14-mHh.jpg",
            "publishedAt": "2023-09-30T02:48:50Z",
            "content": "The market for obesity and weight management drugs is attracting a lot of interest lately in the United States. Patients are gradually understanding the benefits of obesity drugs like Novo Nordisks N\u2026 [+6125 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Publicnow",
            "title": "Eli Lilly and : Lilly Statement on Mounjaro\u00ae (tirzepatide) Compounding Litigation",
            "description": "(marketscreener.com) \n \n Lilly Statement on Mounjaro\u00ae Compounding Litigation\n \n \n September 19, 2023\n \n \n Lilly filed this lawsuit to protect patients. Lilly cannot validate the safety or effectiveness of products claiming to contain tirzepatide that are not \u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-and-Lilly-Statement-on-Mounjaro-tirzepatide-Compounding-Litigation-44878793/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-09-19T19:21:02Z",
            "content": "Lilly Statement on Mounjaro\u00ae (tirzepatide) Compounding Litigation\r\nSeptember 19, 2023\r\nLilly filed this lawsuit to protect patients. Lilly cannot validate the safety or effectiveness of products clai\u2026 [+1563 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Eli Lilly and : Lilly Statement Regarding Terrorist Attack on Israel",
            "description": "(marketscreener.com) \n \n Lilly Statement Regarding Terrorist Attack on Israel\n \n \n October 12, 2023\n \n \n We are heartbroken and outraged by the horrible terrorist atrocities in Israel this past weekend that targeted innocent men, women and children. Lilly joi\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-and-Lilly-Statement-Regarding-Terrorist-Attack-on-Israel-45053691/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-12T20:48:03Z",
            "content": "Lilly Statement Regarding Terrorist Attack on Israel\r\nOctober 12, 2023\r\nWe are heartbroken and outraged by the horrible terrorist atrocities in Israel this past weekend that targeted innocent men, wo\u2026 [+682 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Dow Jones",
            "title": "Eli Lilly Diabetes, Obesity Head Mike Mason to Retire",
            "description": "(marketscreener.com) \n By Colin Kellaher \n\n\n The head of Eli Lilly's burgeoning diabetes and obesity franchise is retiring at the end of the year. \n\n Eli Lilly on Wednesday said Mike Mason, executive vice president and president of Lilly Diabetes & Obesity, i\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-Diabetes-Obesity-Head-Mike-Mason-to-Retire-44981368/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-04T11:31:03Z",
            "content": "By Colin Kellaher \r\nThe head of Eli Lilly's burgeoning diabetes and obesity franchise is retiring at the end of the year. \r\nEli Lilly on Wednesday said Mike Mason, executive vice president and presid\u2026 [+892 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Reuters",
            "title": "Eli Lilly settles whistleblower lawsuit over manufacturing problems",
            "description": "(marketscreener.com) Eli Lilly and Co and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs, accor\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-settles-whistleblower-lawsuit-over-manufacturing-problems-44946831/",
            "urlToImage": "https://img.zonebourse.com/reuters/2020-10/2020-10-08T025809Z_1_LYNXMPEG9705S_RTROPTP_3_HEALTH-CORONAVIRUS-LILLY.JPG",
            "publishedAt": "2023-09-28T21:17:48Z",
            "content": "(Reuters) - Eli Lilly and Co and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification inv\u2026 [+1957 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Reuters",
            "title": "Eli Lilly to buy Point Biopharma for $1.4 billion",
            "description": "(marketscreener.com) Eli Lilly and Co has agreed to\nacquire Point Biopharma Global in an all-cash deal\nvalued at $1.4 billion, the two companies said on Tuesday.\n \n https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-to-buy-P\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-to-buy-Point-Biopharma-for-1-4-billion-44971497/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-03T10:51:20Z",
            "content": "October 03, 2023 at 06:51 am EDT\r\nOct 3 (Reuters) - Eli Lilly and Co has agreed to\r\nacquire Point Biopharma Global in an all-cash deal\r\nvalued at $1.4 billion, the two companies said on Tuesday.\r\n(Re\u2026 [+63 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "wsj.com",
            "title": "Eli Lilly Diabetes, Obesity Head to Retire",
            "description": "The head of Eli Lilly\u2019s burgeoning diabetes and obesity franchise is retiring at the end of the year. Mike Mason is leaving after 34 years with the company. #elilillys #mikemason",
            "url": "https://biztoc.com/x/f276223429984a58",
            "urlToImage": "https://c.biztoc.com/p/f276223429984a58/s.webp",
            "publishedAt": "2023-10-04T11:50:06Z",
            "content": "The head of Eli Lillys burgeoning diabetes and obesity franchise is retiring at the end of the year. Mike Mason is leaving after 34 years with the company.\r\n#elilillys#mikemason\r\nThis story appeared \u2026 [+12 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Reuters",
            "title": "U.S. FDA declines to approve Eli Lilly's skin disease drug",
            "description": "(marketscreener.com) The U.S. Food and Drug Administration\nhas declined to approve Eli Lilly's drug to treat a type\nof skin disease due to certain findings during an inspection of\na contract manufacturer, the company said on Monday.\n\n https://www.marketscreen\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/U-S-FDA-declines-to-approve-Eli-Lilly-s-skin-disease-drug-44963031/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-02T10:51:28Z",
            "content": "October 02, 2023 at 06:51 am EDT\r\nOct 2 (Reuters) - The U.S. Food and Drug Administration\r\nhas declined to approve Eli Lilly's drug to treat a type\r\nof skin disease due to certain findings during an \u2026 [+129 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Eli Lilly to Pay $2.4 Million to Settle Age-Discrimination Suit -- Update",
            "description": "(marketscreener.com) \n By Will Feuer \n\n\n Eli Lilly has agreed to pay $2.4 million to settle an age-discrimination lawsuit brought by the U.S. Equal Employment Opportunity Commission. \n\n Lilly denied positions to pharmaceutical sales representative applicants \u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-to-Pay-2-4-Million-to-Settle-Age-Discrimination-Suit-Update-45051964/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-12T15:41:05Z",
            "content": "By Will Feuer \r\nEli Lilly has agreed to pay $2.4 million to settle an age-discrimination lawsuit brought by the U.S. Equal Employment Opportunity Commission. \r\nLilly denied positions to pharmaceutica\u2026 [+1562 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Reuters",
            "title": "Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion",
            "description": "(marketscreener.com) Eli Lilly and Co will buy\ncancer therapy developer Point Biopharma Global for $1.4\nbillion, the companies said on Tuesday.\n Lilly has offered $12.50 per Point Biopharma share held,\nrepresenting a premium of about 87% to the stock's last c\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-to-buy-cancer-focused-Point-Biopharma-for-1-4-billion-44971680/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-03T11:02:43Z",
            "content": "Oct 3 (Reuters) - Eli Lilly and Co will buy\r\ncancer therapy developer Point Biopharma Global for $1.4\r\nbillion, the companies said on Tuesday.\r\nLilly has offered $12.50 per Point Biopharma share held\u2026 [+252 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Eli Lilly to Pay $2.4 Million to Settle Age-Discrimination Suit",
            "description": "(marketscreener.com) \n By Will Feuer \n\n Eli Lilly has agreed to pay $2.4 million to settle an age-discrimination lawsuit brought by the U.S. Equal Employment Opportunity Commission. \n\n Lilly denied positions to pharmaceutical sales representative applicants d\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-to-Pay-2-4-Million-to-Settle-Age-Discrimination-Suit-45051513/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-12T14:38:04Z",
            "content": "By Will Feuer \r\nEli Lilly has agreed to pay $2.4 million to settle an age-discrimination lawsuit brought by the U.S. Equal Employment Opportunity Commission. \r\nLilly denied positions to pharmaceutica\u2026 [+1346 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "PRNewswire",
            "title": "Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics",
            "description": "(marketscreener.com) \n\nINDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company , today announced that preclinical data for agents targeting KRAS G12D, multiple oncogenic KRAS mutations and Nectin-4, will be presented \u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Loxo-Lilly-Unveils-Three-New-Oncology-Programs-at-2023-AACR-NCI-EORTC-International-Conference-on-Mo-44984070/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-04T16:06:04Z",
            "content": "INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents targeting KRAS G12D, multiple oncogenic\u2026 [+4884 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "CNBC"
            },
            "author": "Natalie Rice",
            "title": "How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company",
            "description": "How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company",
            "url": "https://www.cnbc.com/2023/10/10/ozempic-wegovy-novo-nordisk.html",
            "urlToImage": "https://image.cnbcfm.com/api/v1/image/107314007-1696883856180-GettyImages-1581639572.jpeg?v=1696950001&w=1920&h=1080",
            "publishedAt": "2023-10-10T15:00:00Z",
            "content": "Danish drugmaker Novo Nordisk has entered a new chapter in its 100-year history thanks to its newfound success with two products: Ozempic and Wegovy.\u00a0\r\nThe drugs are once-weekly injectables of a medi\u2026 [+2021 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "reuters.com",
            "title": "Eli Lilly settles whistleblower lawsuit over manufacturing problems",
            "description": "[1/2] An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing Rights Sept 28 (Reuters) - Eli Lilly and C\u2026",
            "url": "https://biztoc.com/x/58c6af94bea40abe",
            "urlToImage": "https://c.biztoc.com/p/58c6af94bea40abe/s.webp",
            "publishedAt": "2023-09-29T01:46:15Z",
            "content": "[1/2] An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo \u2026 [+297 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "reuters.com",
            "title": "Lilly eyes targeted cancer therapies with $1.4 billion Point Biopharma deal",
            "description": "An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing Rights Oct 3 (Reuters) - Eli Lilly and Co (LLY.N\u2026",
            "url": "https://biztoc.com/x/e4c371e8d876f333",
            "urlToImage": "https://c.biztoc.com/p/e4c371e8d876f333/og.webp",
            "publishedAt": "2023-10-03T16:00:19Z",
            "content": "An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo Acquir\u2026 [+292 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Dow Jones",
            "title": "Trending: Eli Lilly to Buy Point Biopharma in $1.4 Billion Deal to Expand Oncology Therapies",
            "description": "(marketscreener.com) \n 14:02 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Lilly plans to acquire Point Biopharma Global, a radiopharmaceutical company with a pipeline\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Trending-Eli-Lilly-to-Buy-Point-Biopharma-in-1-4-Billion-Deal-to-Expand-Oncology-Therapies-44975221/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-03T18:19:01Z",
            "content": "14:02 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Lilly plans to acquire Point Biopharma Global, a radiop\u2026 [+675 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investing.com"
            },
            "author": "Investing.com",
            "title": "Eli Lilly: Diabetes & Obesity president to retire; shares dip",
            "description": "Eli Lilly: Diabetes & Obesity president to retire; shares dip",
            "url": "https://www.investing.com/news/stock-market-news/eli-lilly-diabetes--obesity-president-to-retire-shares-dip-432SI-3190128",
            "urlToImage": "https://i-invdn-com.investing.com/news/EliLilly_800x533_L_1597822002.jpg",
            "publishedAt": "2023-10-04T11:09:06Z",
            "content": "Eli Lilly and Company (NYSE:LLY)\u00a0announced today that Mike Mason, who has served as executive vice president (EVP) and president of Lilly Diabetes and Obesity for 34 years, will retire at the end of \u2026 [+748 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Reuters",
            "title": "Eli Lilly sues over US sales of bogus Mounjaro for weight loss",
            "description": "(marketscreener.com) Eli Lilly on Tuesday said it\nwas suing 10 U.S. medical spas, wellness centers and compounding\npharmacies for selling products claiming to contain tirzepatide,\nthe active ingredient in its diabetes drug Mounjaro which is\nexpected to be app\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-sues-over-US-sales-of-bogus-Mounjaro-for-weight-loss-44878729/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-09-19T18:59:21Z",
            "content": "Sept 19 (Reuters) - Eli Lilly on Tuesday said it\r\nwas suing 10 U.S. medical spas, wellness centers and compounding\r\npharmacies for selling products claiming to contain tirzepatide,\r\nthe active ingred\u2026 [+2727 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Eli Lilly's Mirikizumab Hits Key Phase 3 Goals in Crohn's Disease",
            "description": "(marketscreener.com) \n By Colin Kellaher \n\n\n Eli Lilly on Thursday said a Phase 3 study of its investigational drug mirikizumab met the co-primary and all major secondary endpoints in the treatment of adults with moderately to severely active Crohn's disease.\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-s-Mirikizumab-Hits-Key-Phase-3-Goals-in-Crohn-s-Disease-45049515/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-12T11:42:03Z",
            "content": "By Colin Kellaher \r\nEli Lilly on Thursday said a Phase 3 study of its investigational drug mirikizumab met the co-primary and all major secondary endpoints in the treatment of adults with moderately \u2026 [+888 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Insurance Journal"
            },
            "author": "Admin",
            "title": "EU Probes Anesthesia Complication for New Weight-Loss Drugs",
            "description": "European authorities are investigating whether popular weight-loss and diabetes drugs including Novo Nordisk A/S\u2019s Wegovy may be linked to complications during anesthesia. The European Medicines Agency\u2019s safety committee, PRAC, is discussing the potential saf\u2026",
            "url": "https://www.insurancejournal.com/news/international/2023/09/29/742263.htm",
            "urlToImage": "https://www.insurancejournal.com/app/uploads/2023/09/novo-nordisks-wegovy-weight-loss-drug-bloomberg-scaled.jpg",
            "publishedAt": "2023-09-29T09:42:15Z",
            "content": "European authorities are investigating whether popular weight-loss and diabetes drugs including Novo Nordisk A/S\u2019s Wegovy may be linked to complications during anesthesia.\r\nThe European Medicines Age\u2026 [+2034 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Reuters",
            "title": "US judge overturns Eli Lilly's $176.5 million loss in Teva patent case",
            "description": "(marketscreener.com) Drugmaker Eli Lilly\nconvinced a federal judge in Massachusetts on Tuesday to\noverturn a $176.5 million jury verdict for Teva Pharmaceutical\nthat found Lilly's migraine drug Emgality infringed\nthree patents related to Teva's rival drug Ajo\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/US-judge-overturns-Eli-Lilly-s-176-5-million-loss-in-Teva-patent-case-44925023/",
            "urlToImage": "https://img.zonebourse.com/reuters/2020-10/2020-10-08T025809Z_1_LYNXMPEG9705S_RTROPTP_3_HEALTH-CORONAVIRUS-LILLY.JPG",
            "publishedAt": "2023-09-26T20:27:05Z",
            "content": "Sept 26 (Reuters) - Drugmaker Eli Lilly\r\nconvinced a federal judge in Massachusetts on Tuesday to\r\noverturn a $176.5 million jury verdict for Teva Pharmaceutical\r\nthat found Lilly's migraine drug Emg\u2026 [+1191 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Dow Jones",
            "title": "Eli Lilly, Boehringer Ingelheim Get FDA OK for Jardiance in Chronic Kidney Disease",
            "description": "(marketscreener.com) \n By Colin Kellaher \n\n\n Eli Lilly and Boehringer Ingelheim have won expanded U.S. Food and Drug Administration approval of their blockbuster diabetes drug Jardiance for certain adults with chronic kidney disease. \n\n The companies on Frida\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-Boehringer-Ingelheim-Get-FDA-OK-for-Jardiance-in-Chronic-Kidney-Disease-44905303/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-09-22T13:05:02Z",
            "content": "By Colin Kellaher \r\nEli Lilly and Boehringer Ingelheim have won expanded U.S. Food and Drug Administration approval of their blockbuster diabetes drug Jardiance for certain adults with chronic kidney\u2026 [+958 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "PRNewswire",
            "title": "Lilly Announces Details of Presentations at ESMO Congress 2023",
            "description": "(marketscreener.com) \n\nINDIANAPOLIS, Oct. 6, 2023 /PRNewswire/ -- Eli Lilly and Company today announced that data from studies of Verzenio\u00ae , Retevmo\u00ae , and imlunestrant will be presented at the 2023 European Society for Medical Oncology Congress taking place\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Lilly-Announces-Details-of-Presentations-at-ESMO-Congress-2023-45000874/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-06T11:46:03Z",
            "content": "INDIANAPOLIS, Oct. 6, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio\u00ae (abemaciclib; a CDK4/6 inhibitor), Retevmo\u00ae (selpercatinib; a rearrang\u2026 [+41158 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Yahoo Entertainment"
            },
            "author": "Fahad Saleem",
            "title": "17 Best Low Risk Investments in 2023",
            "description": "In this article, we will take a look at the 16 best low risk investments in 2023. To see more such companies, go directly to 5 Best Low Risk Investments in...",
            "url": "https://finance.yahoo.com/news/17-best-low-risk-investments-213615086.html",
            "urlToImage": "https://s.yimg.com/ny/api/res/1.2/pOGrzBCx8w_VEO_qDAmxaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/b9857e6319b367b43f3701099e17b7f1",
            "publishedAt": "2023-09-17T21:36:15Z",
            "content": "In this article, we will take a look at the 16 best low risk investments in 2023. To see more such companies, go directly to 5 Best Low Risk Investments in 2023.\r\nInvestors are still in a wait and se\u2026 [+16145 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investor's Business Daily"
            },
            "author": "Investor's Business Daily",
            "title": "Dow Jones Sinks After Strong Jobs Data; Warren Buffett Sells More Stock",
            "description": "Dow Jones falls after strong jobs data from the JOLTS report; Yields Spook Stocks As Warren Buffett Sells More HPQ stock.",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-after-strong-jobs-data-yields-spook-stocks-as-warren-buffett-sells-more-stock/",
            "urlToImage": "https://www.investors.com/wp-content/uploads/2020/08/Stock-WallStreetSign-flag08-adobe.jpg",
            "publishedAt": "2023-10-03T14:56:35Z",
            "content": "The Dow Jones Industrial Average fell 0.9% in early trading Tuesday after strong jobs data. The index is testing June's lows as yields continue to spiral upward.\r\nXThe S&amp;P 500 fell 1% at 10:30 a.\u2026 [+3679 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investor's Business Daily"
            },
            "author": "Investor's Business Daily",
            "title": "There's Still Time To Own 13 Stocks That Finish The Year Strong",
            "description": "Why settle for stocks limping to the finish line?",
            "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-theres-still-time-to-own-stocks-that-finish-the-year-strong/",
            "urlToImage": "https://www.investors.com/wp-content/uploads/2023/06/Stock-muscles-adobe.jpg",
            "publishedAt": "2023-10-03T12:00:44Z",
            "content": "Why settle for stocks limping to the finish line? Some investors found S&amp;P 500 stocks that finish the year on a tear.\r\nXThirteen S&amp;P 500 stocks including tech plays like Broadcom (AVGO) and L\u2026 [+5102 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "forbes.com",
            "title": "Eli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion",
            "description": "American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manufacturers struggle to keep up with the challenges of producing modern cancer treatments. Eli\u2026",
            "url": "https://biztoc.com/x/1b2acf7cc37b7f92",
            "urlToImage": "https://c.biztoc.com/p/1b2acf7cc37b7f92/s.webp",
            "publishedAt": "2023-10-03T15:24:06Z",
            "content": "American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manufacturers struggle to keep up wi\u2026 [+306 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "fiercebiotech.com",
            "title": "Lilly to surf radiopharmaceutical wave with $1.4B acquisition of Point Biopharma",
            "description": "Eli Lilly is snapping up Point Biopharma Global for $1.4 billion, marking an official entrance into the radiopharmaceutical cancer therapeutic space. | Eli Lilly is snapping up Point Biopharma Global, acquiring the radiopharmaceutical cancer company for $1.4 \u2026",
            "url": "https://biztoc.com/x/28e00fad17a564ec",
            "urlToImage": "https://c.biztoc.com/p/28e00fad17a564ec/og.webp",
            "publishedAt": "2023-10-03T18:46:09Z",
            "content": "Eli Lilly is snapping up Point Biopharma Global for $1.4 billion, marking an official entrance into the radiopharmaceutical cancer therapeutic space. | Eli Lilly is snapping up Point Biopharma Global\u2026 [+184 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "reuters.com",
            "title": "Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion",
            "description": "FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo (Reuters) - Eli Lilly and Co has agreed to acquire Poi\u2026",
            "url": "https://biztoc.com/x/51d3efd16ede30ac",
            "urlToImage": "https://c.biztoc.com/p/51d3efd16ede30ac/s.webp",
            "publishedAt": "2023-10-03T11:04:05Z",
            "content": "FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File \u2026 [+292 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investing.com"
            },
            "author": "Reuters",
            "title": "Eli Lilly settles whistleblower lawsuit over manufacturing problems",
            "description": "Eli Lilly settles whistleblower lawsuit over manufacturing problems",
            "url": "https://www.investing.com/news/stock-market-news/eli-lilly-settles-whistleblower-lawsuit-over-manufacturing-problems-3185775",
            "urlToImage": "https://i-invdn-com.investing.com/news/EliLilly_800x533_L_1604420191.jpg",
            "publishedAt": "2023-09-28T21:21:13Z",
            "content": "By Dan Levine and Marisa Taylor\r\n(Reuters) - Eli Lilly (NYSE:LLY) and Co and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufa\u2026 [+1866 chars]"
        },
        {
            "source": {
                "id": "cbs-news",
                "name": "CBS News"
            },
            "author": "Alexander Tin",
            "title": "Is your Ozempic pen fake? Group warns of counterfeit weight loss drugs",
            "description": "The warning about scams comes as sales have boomed for Ozempic, Wegovy and other drugs used for weight loss.",
            "url": "https://www.cbsnews.com/news/ozempic-wegovy-fake-weight-loss-drugs-fda-investigating-trade-group-warns/",
            "urlToImage": "https://assets3.cbsnewsstatic.com/hub/i/r/2023/05/03/d470addf-134d-41f4-b119-72d0c5d43e62/thumbnail/1200x630/189d27f6b9fcacac2665eecad0576530/ozempic.jpg?v=42bbcea0e3eaab3fb7d470f54c86b0bd",
            "publishedAt": "2023-10-05T16:58:00Z",
            "content": "The Food and Drug Administration is now investigating an array of fraudulent schemes that appear to be trafficking counterfeit versions of Ozempic, an industry trade group recently warned its members\u2026 [+4432 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Dow Jones",
            "title": "FDA Turns Away Eli Lilly Eczema Drug Due to Manufacturing Issue",
            "description": "(marketscreener.com) \n By Colin Kellaher \n\n\n The U.S. Food and Drug Administration has turned away Eli Lilly's application seeking approval of lebrikizumab due to findings that arose during a multi-sponsor inspection of a contract manufacturing organization t\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/FDA-Turns-Away-Eli-Lilly-Eczema-Drug-Due-to-Manufacturing-Issue-44963272/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-02T11:11:03Z",
            "content": "By Colin Kellaher \r\nThe U.S. Food and Drug Administration has turned away Eli Lilly's application seeking approval of lebrikizumab due to findings that arose during a multi-sponsor inspection of a co\u2026 [+683 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "PRNewswire",
            "title": "U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer",
            "description": "(marketscreener.com) \n\nIn the letter, the FDA stated no concerns about the clinical data package, safety or label for lebrikizumab\nINDIANAPOLIS, Oct. 2, 2023 /PRNewswire/ -- Eli Lilly and Company announced that the U.S. Food and Drug Administration has issued\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/U-S-Food-and-Drug-Administration-Issues-Complete-Response-Letter-for-Lebrikizumab-Based-on-Inspecti-44962967/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-10-02T10:46:04Z",
            "content": "In the letter, the FDA stated no concerns about the clinical data package, safety or label for lebrikizumab\r\nINDIANAPOLIS, Oct. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:\u00a0LLY) announced tha\u2026 [+4001 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Dow Jones",
            "title": "Trending : Eli Lilly's Head of Diabetes, Obesity to Retire",
            "description": "(marketscreener.com) \n 10:07 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The drugmaker said Mike Mason, president of its diabetes and obesity franchise, is retiring \u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Trending-Eli-Lilly-s-Head-of-Diabetes-Obesity-to-Retire-44983281/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-04T14:24:02Z",
            "content": "10:07 ET -- Eli Lilly is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The drugmaker said Mike Mason, president of its diabete\u2026 [+203 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "Reuters",
            "title": "ELI LILLY SAYS SUED SIX U.S. MEDICAL SPAS AND WELLNESS CENTERS F\u2026",
            "description": "(marketscreener.com) \n ELI LILLY SAYS SUED SIX U.S. MEDICAL SPAS AND WELLNESS CENTERS FOR SELLING PRODUCTS ADVERTISED AS MOUNJARO\n https://www.marketscreener.com/news/latest/ELI-LILLY-SAYS-SUED-SIX-U-S-MEDICAL-SPAS-AND-WELLNESS-CENTERS-F-8230--44878709/?utm_m\u2026",
            "url": "https://www.marketscreener.com/news/latest/ELI-LILLY-SAYS-SUED-SIX-U-S-MEDICAL-SPAS-AND-WELLNESS-CENTERS-F-8230--44878709/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-09-19T18:59:21Z",
            "content": "ANALYST RECOMMENDATIONS : Adobe, Apple, Dell, Eli Lilly, NatWest...\r\nEvery morning, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies t\u2026 [+240 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "cnn.com",
            "title": "Maker of diabetes drug Mounjaro takes legal action against compounders, spas and wellness centers",
            "description": "Pharmaceutical company Eli Lilly has filed several lawsuits against certain US medical spas, wellness centers and compounding pharmacies in an attempt to stop them from \u201cthe unlawful marketing and sale of non-FDA approved compounded products\u201d which the compan\u2026",
            "url": "https://biztoc.com/x/42ffebda24500e23",
            "urlToImage": "https://c.biztoc.com/p/42ffebda24500e23/og.webp",
            "publishedAt": "2023-09-19T21:08:18Z",
            "content": "Pharmaceutical company Eli Lilly has filed several lawsuits against certain US medical spas, wellness centers and compounding pharmacies in an attempt to stop them from the unlawful marketing and sal\u2026 [+278 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Global markets live: BAE Systems, UBS, Apple, Walmart, Eli Lilly...",
            "description": "(marketscreener.com) Every day, the MarketScreener team selects the most important news about listed companies across the world. Here's a short recap for your convenience:https://www.marketscreener.com/news/latest/Global-markets-live-BAE-Systems-UBS-Apple-Wal\u2026",
            "url": "https://www.marketscreener.com/news/latest/Global-markets-live-BAE-Systems-UBS-Apple-Walmart-Eli-Lilly---44965676/",
            "urlToImage": "https://img.zonebourse.com/reuters/2018-05/2018-05-07T170408Z_1_LYNXMPEE4618T_RTROPTP_3_USA-STOCKS.JPG",
            "publishedAt": "2023-10-02T15:19:19Z",
            "content": "ANALYST RECOMMENDATIONS : Amgen, Best Buy, Comcast, Fedex, Mosaic...\r\nEvery morning, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies \u2026 [+241 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investing.com"
            },
            "author": "Reuters",
            "title": "Eli Lilly sues over US sales of bogus Mounjaro for weight loss",
            "description": "Eli Lilly sues over US sales of bogus Mounjaro for weight loss",
            "url": "https://www.investing.com/news/stock-market-news/eli-lilly-sues-over-us-sales-of-bogus-mounjaro-for-weight-loss-3177804",
            "urlToImage": "https://i-invdn-com.investing.com/news/EliLilly_800x533_L_1604420191.jpg",
            "publishedAt": "2023-09-19T19:11:42Z",
            "content": "By Patrick Wingrove\r\n(Reuters) - Eli Lilly (NYSE:LLY) on Tuesday said it was suing 10 U.S. medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepati\u2026 [+2659 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": "PRNewswire",
            "title": "Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies",
            "description": "(marketscreener.com) \n\nINDIANAPOLIS, Oct. 3, 2023 /PRNewswire/ --\u00a0Eli Lilly and Company and\u00a0POINT Biopharma Global, Inc. today announced a definitive agreement for\u00a0Lilly\u00a0to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinic\u2026",
            "url": "https://www.marketscreener.com/quote/stock/POINT-BIOPHARMA-GLOBAL-IN-124363438/news/Lilly-to-Acquire-POINT-Biopharma-to-Expand-Oncology-Capabilities-into-Next-Generation-Radioligand-Th-44971453/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-03T10:46:04Z",
            "content": "INDIANAPOLIS, Oct. 3, 2023 /PRNewswire/ --\u00a0Eli Lilly and Company (NYSE: LLY) and\u00a0POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for\u00a0Lilly\u00a0to acquire POINT, a radiop\u2026 [+13089 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Medicare removes coverage curb on PET scans for Alzheimer's patients",
            "description": "(marketscreener.com) The U.S. Centers for Medicare and\nMedicaid Services on Friday removed a national policy that\nrestricted coverage for a type of brain scan called PET needed\nby doctors to determine if patients are eligible for newly\ndeveloped Alzheimer's d\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Medicare-removes-coverage-curb-on-PET-scans-for-Alzheimer-s-patients-45061265/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-13T14:25:21Z",
            "content": "Oct 13 (Reuters) - The U.S. Centers for Medicare and\r\nMedicaid Services on Friday removed a national policy that\r\nrestricted coverage for a type of brain scan called PET needed\r\nby doctors to determi\u2026 [+316 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "The New York Review of Books"
            },
            "author": "Daniel J. Kevles",
            "title": "Unreasonable Terms",
            "description": "One of the main corporate participants in Operation Warp Speed, the Trump administration\u2019s multibillion-dollar crash program to create and produce a Covid-19 vaccine, was Moderna. The federal government gave Moderna, which in 2019 was a small, unprofitable ph\u2026",
            "url": "https://www.nybooks.com/articles/2023/10/05/unreasonable-terms-owning-the-sun-monopoly-medicine/",
            "urlToImage": "https://www.nybooks.com/wp-content/uploads/2023/09/kevles_1-100523-900.jpg",
            "publishedAt": "2023-09-14T12:00:00Z",
            "content": "One of the main corporate participants in Operation Warp Speed, the Trump administration\u2019s multibillion-dollar crash program to create and produce a Covid-19 vaccine, was Moderna. The federal governm\u2026 [+34252 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Zacks.com"
            },
            "author": "247patrick",
            "title": "The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J",
            "description": "Featured stocks include AbbVie and Johnson & Johnson.",
            "url": "https://www.zacks.com/stock/news/2158561/the-zacks-analyst-blog-highlights-abbvie-lilly-sanofi-merck",
            "urlToImage": "https://247wallst.com/wp-content/uploads/2022/03/imageForEntry1-1b7.jpg",
            "publishedAt": "2023-10-03T02:45:31Z",
            "content": "Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks\u2026 [+6538 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Analyst recommendations: Adobe, Apple, Dell, Eli Lilly, NatWest...",
            "description": "(marketscreener.com) Every morning, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or of a new coverage. It may be updated du\u2026",
            "url": "https://www.marketscreener.com/news/latest/Analyst-recommendations-Adobe-Apple-Dell-Eli-Lilly-NatWest---44874316/",
            "urlToImage": "https://img.zonebourse.com/reuters/2023-09/2023-09-15T111415Z_1_LYNXMPEJ8E0ER_RTROPTP_3_APPLE-FRANCE-EXPLAINER.JPG",
            "publishedAt": "2023-09-19T09:33:47Z",
            "content": "Every morning, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or \u2026 [+1457 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Relevantmagazine.com"
            },
            "author": "Newt Crenshaw",
            "title": "How the Church Can Help Fight the Loneliness Epidemic",
            "description": "The U.S. Surgeon General recently reported that loneliness is sweeping America, even classifying it as an \u201cepidemic.\u201d The study shows the health risks of being lonely are now just as damaging as a person smoking 15 cigarettes a day, and loneliness actually in\u2026",
            "url": "https://relevantmagazine.com/life5/how-the-church-can-help-fight-the-loneliness-epidemic/",
            "urlToImage": "https://relevantmagazine.com/wp-content/uploads/2023/09/How-the-Church-Can-Help-Fight-the-Loneliness-Epidemic_Feature_RLV_2023-scaled.jpg",
            "publishedAt": "2023-09-19T14:25:49Z",
            "content": "The U.S. Surgeon General recentlyreported that loneliness is sweeping America, even classifying it as an epidemic. The study shows the health risks of being lonely are now just as damaging as a perso\u2026 [+5340 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Sitryx Therapeutics",
            "title": "Sitryx raises additional $39 million to progress development of disease-modifying therapeutics for chronic autoimmune and inflammatory disease",
            "description": "Oxford, UK \u2013 27 September 2023 \u2013 Sitryx Therapeutics (\u201cthe Company\u201d), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces the successful \u2026",
            "url": "https://www.globenewswire.com/news-release/2023/09/27/2750055/0/en/Sitryx-raises-additional-39-million-to-progress-development-of-disease-modifying-therapeutics-for-chronic-autoimmune-and-inflammatory-disease.html",
            "urlToImage": "https://ml-eu.globenewswire.com/Resource/Download/34f3226d-9b3e-4c74-8115-15bf66f12b4e",
            "publishedAt": "2023-09-27T06:00:00Z",
            "content": "<ul><li>Oxford Science Enterprises (OSE)joins existing investors SV Health Investors, Lilly, Sofinnova Partners, Longwood Fund andGSK</li><li>Follows original $30 million Series A raise, and brings t\u2026 [+4689 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "CNBC"
            },
            "author": "Pia Singh",
            "title": "Stocks making the biggest moves midday: Splunk, Cisco, Broadcom, Fox and more",
            "description": "These are the stocks posting the largest moves in midday trading.",
            "url": "https://www.cnbc.com/2023/09/21/stocks-making-the-biggest-moves-midday-splk-foxa-avgo-csco.html",
            "urlToImage": "https://image.cnbcfm.com/api/v1/image/107270136-1689157721830-gettyimages-1321540122-_09i1556_20210603112227010.jpeg?v=1695315338&w=1920&h=1080",
            "publishedAt": "2023-09-21T16:55:00Z",
            "content": "Check out the companies making headlines in midday trading.\r\nCisco Systems, Splunk Shares of Cisco fell 4.2% on Thursday after the company said it is acquiring cybersecurity software company Splunk f\u2026 [+2264 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Lithub.com"
            },
            "author": "Stuart Bradwel",
            "title": "\u201cOne of the Single Most Expensive Substances on the Planet\u201d: The Insulin Crisis of the 21st Century",
            "description": "In 2017, almost a hundred years after insulin was \u2018defensively\u2019 patented for the express purpose of preventing unethical profiteering, Alec Smith was found dead in his Minneapolis home at only 26 years old. He had been diagnosed with T1DM two years previously\u2026",
            "url": "https://lithub.com/one-of-the-single-most-expensive-substances-on-the-planet-the-insulin-crisis-of-the-21st-century/",
            "urlToImage": "https://s26162.pcdn.co/wp-content/uploads/2023/09/insulin-1.jpg",
            "publishedAt": "2023-09-25T08:38:32Z",
            "content": "In 2017, almost a hundred years after insulin was defensively patented for the express purpose of preventing unethical profiteering, Alec Smith was found dead in his Minneapolis home at only 26 years\u2026 [+13694 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Analyst recommendations: 3M, Amgen, Eli Lilly, PepsiCo, Charles Schwabb...",
            "description": "(marketscreener.com) Every morning, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or of a new coverage. It may be updated du\u2026",
            "url": "https://www.marketscreener.com/news/latest/Analyst-recommendations-3M-Amgen-Eli-Lilly-PepsiCo-Charles-Schwabb---45018248/",
            "urlToImage": "https://img.zonebourse.com/reuters/2022-10/2022-10-12T101650Z_1_LYNXMPEI9B0JQ_RTROPTP_3_PEPSICO-RESULTS.JPG",
            "publishedAt": "2023-10-09T09:46:22Z",
            "content": "Every morning, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or \u2026 [+4497 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investor's Business Daily"
            },
            "author": "Investor's Business Daily",
            "title": "WW Stock Soars To High. New Weight-Loss Drug Play Enjoys Oprah Winfrey Effect.",
            "description": "The ex WeightWatchers is reinventing itself amid boom for weight-loss drugs like Ozempic.",
            "url": "https://www.investors.com/news/ww-stock-soars-high-highsweight-loss-drug-play-oprah-winfrey-effect/",
            "urlToImage": "https://www.investors.com/wp-content/uploads/2023/10/BIZ04oprah101023ap.jpg",
            "publishedAt": "2023-10-10T21:02:39Z",
            "content": "WW International (WW) continues to sizzle after board member Oprah Winfrey clarified that she didn't mean to diss weight-loss drugs. Formerly WeightWatchers, WW stock broke out Tuesday.\r\nXOver the we\u2026 [+2286 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "cnbc.com",
            "title": "Here are Friday's biggest analyst calls: Netflix, Nvidia, Eli Lilly, Disney, Levi's, Exxon, Walmart and more",
            "description": "Here are Friday's biggest calls on Wall Street: Piper Sandler upgrades Shoals to overweight from neutral Piper Sandler said investors should buy the dip in shares of the solar technology company. \"The weakness in SHLS is in part driven by equity weakness of t\u2026",
            "url": "https://biztoc.com/x/0401769e5bc66593",
            "urlToImage": "https://c.biztoc.com/p/0401769e5bc66593/og.webp",
            "publishedAt": "2023-10-06T17:50:20Z",
            "content": "Here are Friday's biggest calls on Wall Street: Piper Sandler upgrades Shoals to overweight from neutral Piper Sandler said investors should buy the dip in shares of the solar technology company. \"Th\u2026 [+283 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investing.com"
            },
            "author": "Reuters",
            "title": "US judge overturns Eli Lilly's $176.5 million loss in Teva patent case",
            "description": "US judge overturns Eli Lilly's $176.5 million loss in Teva patent case",
            "url": "https://www.investing.com/news/stock-market-news/us-judge-overturns-eli-lillys-1765-million-loss-in-teva-patent-case-3183394",
            "urlToImage": "https://i-invdn-com.investing.com/news/LYNXMPED3O0LI_L.jpg",
            "publishedAt": "2023-09-26T20:44:40Z",
            "content": "By Blake Brittain\r\n(Reuters) - Drugmaker Eli Lilly (NYSE:LLY) convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical (NYSE:TEVA) that \u2026 [+1123 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "American Kidney Fund",
            "title": "Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund\u2019s 2023 Corporate Membership Program at \u2018Champion\u2019 Level",
            "description": "ROCKVILLE, Md., Oct. 06, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2023 class in AKF\u2019s Corporate Membership Program as a Champion-level member. Boehringer Ingelh\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/10/06/2756204/0/en/Boehringer-Ingelheim-and-Eli-Lilly-and-Company-Join-American-Kidney-Fund-s-2023-Corporate-Membership-Program-at-Champion-Level.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/9c3b0005-466e-45a7-8e38-b5cc1ce4f154",
            "publishedAt": "2023-10-06T15:28:00Z",
            "content": "ROCKVILLE, Md., Oct. 06, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2023 class in AKFs Corporate Membe\u2026 [+3302 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial",
            "description": "(marketscreener.com) \n\nMirikizumab demonstrated clinical remission and endoscopic response for patients with moderately to severely active Crohn's disease through 52 weeks\nThe study achieved the coprimary endpoints and all major secondary endpoints versus pla\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Lilly-s-Mirikizumab-Helped-Patients-with-Crohn-s-Disease-Achieve-Long-Term-Remission-in-Phase-3-Tria-45048906/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-10-12T10:46:04Z",
            "content": "Mirikizumab demonstrated clinical remission and endoscopic response for patients with moderately to severely active Crohn's disease through 52 weeks\r\nThe study achieved the coprimary endpoints and al\u2026 [+8054 chars]"
        }
    ]
}